Pacific Biosciences (P09) Stock Statistics & Valuation Metrics

Pacific Biosciences has a market cap or net worth of $394.50M. The enterprise value is €934.33M.

Pacific Biosciences has 301,998,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacific Biosciences’s return on equity (ROE) is -102.15 and return on invested capital (ROIC) is -76.41%.

The current PE Ratio of Pacific Biosciences is ―. Pacific Biosciences’s PEG ratio is -0.02.

In the last 12 months, Pacific Biosciences had revenue of 160.00M and earned -546.38M in profits. Earnings per share was -1.82.

In the last 12 months, operating cash flow was -111.21M and capital expenditures -12.71M, giving a free cash flow of -123.92M billion.

Pacific Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Pacific Biosciences upcoming earnings date is May 6, 2026, TBA (Confirmed).

Pacific Biosciences as a current ratio of 6.89, with Debt / Equity ratio of 14198.21%

In the past 12 months, Pacific Biosciences has paid 318.00K in taxes.

Pacific Biosciences EV to EBITDA ratio is -30.44, with an EV/FCF ratio of -9.14.

Pacific Biosciences has $279.51M in cash and marketable securities with $759.46M in debt, giving a net cash position of -$479.96M billion.

Gross margin is 28.21%, with operating margin of -348.46%, and net profit margin of -341.47%.

The average price target for Pacific Biosciences is $2.15, which is 11.43% higher than the current price. The consensus rating is Moderate Buy